High concordance between nonalcoholic fatty liver disease and metabolic dysfunction associated steatotic liver disease in the TARGET-NASH real world cohort.

INTRODUCTION: This study investigates the applicability of the new MASLD nomenclature to the real-world TARGET-NASH US adult cohort.

METHODS: The new MASLD/MASH nomenclature was applied to patients enrolled with pragmatic diagnoses of NAFL, NASH and NASH cirrhosis and concordance was determined between the definitions.

RESULTS: 99% of TARGET-NASH participants met the new MASLD diagnostic criteria. 1484/1541 (96.3%, kappa 0.974) NAFL patients (MASL), 2195/2201 (99.7%, kappa 0.998) NASH patients (MASH), and 1999/2003 (99.8%, kappa 0.999) NASH cirrhosis patients met the new criteria.

CONCLUSION: The new MASLD nomenclature is highly concordant with the prior TARGET-NASH pragmatic definitions.